Palatin Technologies Announces Positive Appetite Suppression Results From BMT-801 Phase 2 Obesity Study

• Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety
• Bremelanotide matched or exceeded tirzepatide in appetite suppression
• Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation

CRANBURY, N.J., April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced positive appetite suppression results from its BMT-801 Phase 2 obesity study. The study included a co-administered melanocortin 4 receptor (MC4R) agonist bremelanotide plus glucagon like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) tirzepatide arm, bremelanotide alone, and tirzepatide alone arms.

Key Results – Appetite Suppression (Patient-Reported Outcomes)

Using a validated daily appetite questionnaire, the study showed that patients receiving co-administered bremelanotide + tirzepatide, tirzepatide alone, and bremelanotide alone, experienced  significant improvements in appetite suppression, fullness, and satiety. Patients who transitioned to placebo after initial weight loss on tirzepatide showed no improvement for appetite suppression.

• Overall appetite suppression
  • Bremelanotide + tirzepatide: 71% increase
  • Tirzepatide only: 73% increase
  • Bremelanotide only: 71% increase
• "How full do you feel (fullness)?"
  • Bremelanotide + tirzepatide: 65% increase
  • Tirzepatide only: 62% increase
  • Bremelanotide only: 79% increase
• "How satisfied do you feel (satiety)?"
  • Bremelanotide + tirzepatide: 56% increase
  • Tirzepatide only: 56% increase
  • Bremelanotide only: 68% increase

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study. In contrast, patients who transitioned to low-dose bremelanotide after initial weight loss on tirzepatide maintained their weight without any significant regain, underscoring the potential of MC4R agonists as a valuable therapy for long-term weight maintenance. 

Topline results from the BMT-801 Phase 2 trial, released last month, demonstrated statistically significant weight loss with bremelanotide co-administered with tirzepatide versus placebo over an 8-week treatment period. Further analysis of secondary and exploratory endpoints—including body composition and BMI—is ongoing.